Navigation Links
Inovio Pharmaceuticals and VGX International to Advance Therapeutic Hepatitis C and Hepatitis B Synthetic Vaccines into Clinical Studies
Date:10/10/2011

ts who have cleared the virus on their own. The responses included strong NS3-specific interferon-γ (IFN-γ) induction, robust CD4 and CD8 T cell proliferation, and induction of polyfunctional T cells. The study was funded in part by a $2.8 million PA CURE grant received by Inovio and its collaborators in 2010 to develop this multi-antigen synthetic HCV vaccine.

"Hepatitis B and C are a major global health problem, with about 470 million people infected worldwide. As a development leader of synthetic vaccines, we are pleased to collaborate with our affiliate VGX International to advance our global, multi-antigen HCV vaccine into the clinic. This latest development is an integral part of Inovio's multi-pronged approach to develop our therapeutic hepatitis vaccine pipeline," stated Dr. J. Joseph Kim, President and CEO.

Inovio has an ongoing open label Phase II clinical study with ChronTech Pharma AB to test the effect of a DNA vaccine (ChronVac-C®) encoding for NS3/4A protein (genotype 1a) administered by Inovio's MedPulser® electroporation delivery device followed by the standard of care (SOC) drug treatment using interferon and ribavirin. In an earlier phase I study, 5 of 6 participants (83%) who received the vaccine along with SOC cleared the virus. SOC drug treatment alone in patients infected with HCV genotype 1 results in clearance of the virus in 40-50% of patients. Interim results from this phase II study are expected in 2012.

Inovio previously announced a research collaboration with ChronTech Pharma AB and Transgene S.A. to test the immunogenicity of a DNA/electroporation prime - MVA boost approach against HCV by combining two promising, previously studied clinical candidates. A Phase I clinical study is anticipated to start in Q4 2011.

Under the same agreement, Inovio and VGX International
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inovio Pharmaceuticals Leadership for Life Sciences Recognized in the Philadelphia Region
2. Inovio Pharmaceuticals Synthetic Vaccine for Cancer Recognized as Most Promising Research at Global Vaccine Congress
3. Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines Potential to Help Ensure Nations Food Supply Safety
4. Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
5. Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board
6. Inovio Pharmaceuticals to Present at Investor Conferences
7. Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results
8. Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I
9. Inovio Pharmaceuticals Announces Transition of Avtar Dhillon to Non-Executive Chairman of the Board
10. Inovio Pharmaceuticals to Present at Scientific & Industry Conferences
11. Inovio Pharmaceuticals Subsidiary, VGX Animal Health, to Present at VetHealth Global 2011, June 14-17, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According ... on medical technology market intelligence, the ... and occlusion (TEO) device markets will expand moderately ... the fastest-growing segments. In particular, increasing interest in ... oncology has fueled rapid growth of these markets. ...
(Date:1/15/2014)... Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ... per share, net to the seller in cash, without ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ... including reductions in body fat content and preserved ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Inc. (Nasdaq: ALXA ) today announced that company ... will present during the MDB Bright Lights Conference 2011.  The ... 10:00 a.m. Eastern Time.  The presentation will be webcast live ... via the Web, please go to the Investor Relations tab ...
... DIEGO, May 6, 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ... to present at the Bank of America Merrill Lynch 2011 Health ... Time (1:00 p.m. Eastern Time) at the Encore at the Wynn ... Ph.D., Arena,s Vice President, Lorcaserin Development, is scheduled to provide a ...
Cached Medicine Technology:Alexza to Present at the MDB Bright Lights Conference 2011 2Alexza to Present at the MDB Bright Lights Conference 2011 3Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference 2Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference 3
(Date:4/14/2014)... Therapeutics, Inc., announced today a publication demonstrating that ... human red blood cells exposed to plasma samples ... anemia (AIHA). The article entitled "TNT003, an inhibitor ... induced by cold agglutinin disease patient autoantibodies" was ... earlier this month. TNT003 is the murine analog ...
(Date:4/14/2014)... around the world, many people live and work in ... block sunlight. And as the global population continues to ... will only spread. , To alleviate the problem, ... redirects sunlight onto narrow streets and alleyways. The panel ... at an angle, where it spreads sunlight onto the ...
(Date:4/14/2014)... professor of chemical engineering at Virginia Tech , ... analyze living cells. The long-term goal is to gain ... In his lab , Lu and his students ... events inside cells. These devices promote high sensitivity and ... cells. , Based on their record of achievements, the ...
(Date:4/14/2014)... April 2014, Perth, Australia. Drug discovery company Proteomics ... development of a companion diagnostic (CDx) test with ... , The research team authenticated the panel of ... control samples. Seven biomarkers were validated at high ... , The mass spectrometry data was then cross-validated ...
(Date:4/14/2014)... guidelines for high-risk bladder cancer, chemotherapy before or ... clinical practice. The findings are published early online ... the American Cancer Society. , Clinical trials have ... muscle-invasive bladder cancer who are given chemotherapy before ... after surgery also improves survival. To investigate the ...
Breaking Medicine News(10 mins):Health News:Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease 2Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2Health News:Efficient analysis of small quantity of cells improves chances to understand disease 2
... /PRNewswire/ -- Aesthetic Medical Educators ... medical professionals on Aesthetic Procedures over the past ... training include physicians, nurses, physician assistants and dentists, ... in his/her practice.These medical professionals have been trained ...
... Convene in Washington D.C. ... Pass Legislation that Will Protect the Public WASHINGTON, April ... of foodborne illness, including surviving family members of those ... Capitol to share their stories, meet with legislators and ...
... -- With the 2009 NBA playoff season ... public affairs television program that tells the compelling and ... and diabetes patient Dominique Wilkins. Sharing Miracles ... stations. A nine-time NBA all-star who spent the majority ...
... Controls Limit Vaccine SuppliesDALLAS, April 29 Fears of ... new vaccines, as well as meeting public demand for ... National Center for Policy Analysis. "We are facing ... six vaccines for common childhood illnesses," said NCPA Senior ...
... Executive Chairman & CEO Douglas MacLellan offers expert insight ... April 29 AMDL Inc. ... major operations in China, announced today its Executive Chairman ... featured in The Wall Street Transcript - ...
... appear to be safe, but more research needed ... shows promise in treating diabetic polyneuropathy, a disorder that ... years, a new study finds. , Researchers in Boston ... (VEGF) gene may help patients with diabetic polyneuropathy. The ...
Cached Medicine News:Health News:Aesthetic Medical Educators Training Successfully Trains Over 2,000 Medical Professionals on Aesthetic Procedures 2Health News:Foodborne Illness Victims Mark President Obama's First 100 Days By Calling For Permanent Fix To Food Safety System 2Health News:Foodborne Illness Victims Mark President Obama's First 100 Days By Calling For Permanent Fix To Food Safety System 3Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 2Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 3Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 4Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 5Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 6Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 7Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 8Health News:Swine Flu Outbreak Illustrates Problems in Vaccine Development 2Health News:Chinese Pharma Market Continues to Grow at a 5-7% Rate in 2009; AMDL Remains on Track to Meet FY09 Financial Targets 2Health News:Chinese Pharma Market Continues to Grow at a 5-7% Rate in 2009; AMDL Remains on Track to Meet FY09 Financial Targets 3Health News:Gene Therapy Improves Diabetic Neuropathy in Study 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: